Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
OncoSil Medical Ltd ( (AU:OSL) ) has provided an update.
OncoSil Medical Limited has released an investor webinar presentation highlighting its recent achievements and future commercial milestones. The company reported record sales of its OncoSil™ device in the fourth quarter of FY25 and is expanding its geographic footprint, including targeting the US market. The presentation also covered upcoming clinical studies in Germany and detailed the allocation of funds from a recent capital raise, indicating strategic growth and enhanced market positioning.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a global medical device company specializing in Interventional Oncology. The company focuses on improving cancer treatment outcomes through the targeted intratumoural placement of Phosphorous-32 Microparticles alongside chemotherapy. Their flagship product, the OncoSil™ device, is designed for treating unresectable locally advanced pancreatic cancer, offering a targeted radiation approach that minimizes damage to surrounding organs. OncoSil™ has received CE Marking approval and is recognized as a breakthrough device in both Europe and the United States, with approval for sale in over 30 countries.
Average Trading Volume: 52,724
Technical Sentiment Signal: Sell
Current Market Cap: A$20.52M
For an in-depth examination of OSL stock, go to TipRanks’ Overview page.